Literature DB >> 29435319

Serum magnesium concentration is independently associated with non-alcoholic fatty liver and non-alcoholic steatohepatitis.

Ahad Eshraghian1, Saman Nikeghbalian2, Bita Geramizadeh2, Seyed Ali Malek-Hosseini2.   

Abstract

BACKGROUND: The pathogenesis of non-alcoholic fatty liver disease (NAFLD) has not been well recognized yet.
OBJECTIVE: This study aimed to investigate the association between serum magnesium concentration and NAFLD.
METHODS: Study participants were healthy individuals who had undergone liver biopsies between January 2012 and August 2015 as a routine pre-transplant check-up before living donor liver transplantation. Liver biopsy specimens were evaluated by an expert pathologist regarding presence of hepatic steatosis and steatohepatitis. Serum magnesium concentration was measured and compared in those with normal liver biopsy and those with steatosis and steatohepatitis.
RESULTS: A total of 226 individuals were included. Eighty-two individuals (36.2%) had hepatic steatosis and 22 (9.7%) individuals had steatohepatitis and steatosis in their liver histology. Lower serum magnesium concentration was independently associated with hepatic steatosis (OR: 0.059; 95% CI: 0.011-0.325, p = 0.001). Serum magnesium concentration was independently associated with steatohepatitis compared to those without steatohepatitis (1.80 ± 0.48 mg/dl and 2.18 ± 0.31 mg/dl) (OR: 0.11; 95% CI: 0.02-0.41, p = 0.001). Serum magnesium concentration was significantly lower in individuals with steatohepatitis (1.80 ± 0.48 mg/dl) compared to individuals without steatosis (2.23 ± 0.31 mg/dl, p < 0.001) and individuals with only steatosis (2.07 ± 0.29 mg/dl, p = 0.017).
CONCLUSION: Serum magnesium concentration is independently associated with hepatic steatosis and steatohepatitis in our study population.

Entities:  

Keywords:  Non-alcoholic fatty liver disease; liver biopsy; magnesium; non-alcoholic steatohepatitis

Year:  2017        PMID: 29435319      PMCID: PMC5802673          DOI: 10.1177/2050640617707863

Source DB:  PubMed          Journal:  United European Gastroenterol J        ISSN: 2050-6406            Impact factor:   4.623


  40 in total

1.  Serum magnesium levels in patients with alcoholic and non-alcoholic fatty liver.

Authors:  L Turecky; V Kupcova; M Szantova; E Uhlikova; A Viktorinova; A Czirfusz
Journal:  Bratisl Lek Listy       Date:  2006       Impact factor: 1.278

Review 2.  Insulin resistance.

Authors:  D C Whitelaw; S G Gilbey
Journal:  Ann Clin Biochem       Date:  1998-09       Impact factor: 2.057

Review 3.  Pathology of non-alcoholic fatty liver disease.

Authors:  Pierre Bedossa
Journal:  Liver Int       Date:  2017-01       Impact factor: 5.828

Review 4.  Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis.

Authors:  Stergios A Polyzos; Konstantinos N Aronis; Jannis Kountouras; Dimitrios D Raptis; Maria F Vasiloglou; Christos S Mantzoros
Journal:  Diabetologia       Date:  2015-09-26       Impact factor: 10.122

Review 5.  Non-alcoholic fatty liver disease and thyroid dysfunction: a systematic review.

Authors:  Ahad Eshraghian; Alireza Hamidian Jahromi
Journal:  World J Gastroenterol       Date:  2014-07-07       Impact factor: 5.742

6.  Insulin increases intracellular magnesium transport in human platelets.

Authors:  D L Hwang; C F Yen; J L Nadler
Journal:  J Clin Endocrinol Metab       Date:  1993-03       Impact factor: 5.958

7.  Vitamin D Deficiency Is Associated With Increased Risk of Non-alcoholic Steatohepatitis in Adults With Non-alcoholic Fatty Liver Disease: Possible Role for MAPK and NF-κB?

Authors:  James E Nelson; Christian L Roth; Laura A Wilson; Katherine P Yates; Bradley Aouizerat; Vicki Morgan-Stevenson; Elizabeth Whalen; Andrew Hoofnagle; Michael Mason; Vivian Gersuk; Matthew M Yeh; Kris V Kowdley
Journal:  Am J Gastroenterol       Date:  2016-03-22       Impact factor: 10.864

8.  Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis.

Authors:  Bashar Mohamad; Vaishal Shah; Mykola Onyshchenko; Mohammed Elshamy; Federico Aucejo; Rocio Lopez; Ibrahim A Hanouneh; Razan Alhaddad; Naim Alkhouri
Journal:  Hepatol Int       Date:  2015-11-11       Impact factor: 6.047

Review 9.  Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes.

Authors:  Andreas L Birkenfeld; Gerald I Shulman
Journal:  Hepatology       Date:  2014-02       Impact factor: 17.425

10.  High dietary magnesium intake is associated with low insulin resistance in the Newfoundland population.

Authors:  Farrell Cahill; Mariam Shahidi; Jennifer Shea; Danny Wadden; Wayne Gulliver; Edward Randell; Sudesh Vasdev; Guang Sun
Journal:  PLoS One       Date:  2013-03-05       Impact factor: 3.240

View more
  8 in total

1.  Cross-sectional analysis of the health profile and dietary intake of a sample of Canadian adults diagnosed with non-alcoholic fatty liver disease.

Authors:  Michelle L Aktary; Lindsay K Eller; Alissa C Nicolucci; Raylene A Reimer
Journal:  Food Nutr Res       Date:  2020-09-18       Impact factor: 3.894

2.  Lower Serum Magnesium Concentrations are associated With Specific Heavy Drinking Markers, Pro-Inflammatory Response and Early-Stage Alcohol-associated Liver Injury§.

Authors:  Vatsalya Vatsalya; Khushboo S Gala; Maithili Mishra; Melanie L Schwandt; John Umhau; Matthew C Cave; Dipendra Parajuli; Vijay A Ramchandani; Craig J McClain
Journal:  Alcohol Alcohol       Date:  2020-03-19       Impact factor: 2.826

3.  Pentoxifylline with metformin treatment improves biochemical parameters in patients with nonalcoholic steatohepatitis.

Authors:  Milica Ćulafić; Sandra Vezmar-Kovačević; Violeta Dopsaj; Branislav Oluić; Nemanja Bidžić; Branislava Miljković; Đorđe Ćulafić
Journal:  J Med Biochem       Date:  2020-09-02       Impact factor: 3.402

4.  Current and emerging pharmacological therapy for non-alcoholic fatty liver disease.

Authors:  Ahad Eshraghian
Journal:  World J Gastroenterol       Date:  2017-11-14       Impact factor: 5.742

5.  Association of Magnesium Intake with Liver Fibrosis among Adults in the United States.

Authors:  Meng-Hua Tao; Kimberly G Fulda
Journal:  Nutrients       Date:  2021-01-02       Impact factor: 5.717

6.  Association of Hypomagnesemia and Liver Injury, Role of Gut-Barrier Dysfunction and Inflammation: Efficacy of Abstinence, and 2-Week Medical Management in Alcohol Use Disorder Patients.

Authors:  Evan J Winrich; Khushboo S Gala; Abhas Rajhans; Christian D Rios-Perez; Amor J Royer; Zarlakhta Zamani; Ranganathan Parthasarathy; Luis S Marsano-Obando; Ashutosh J Barve; Melanie L Schwandt; Vatsalya Vatsalya
Journal:  Int J Mol Sci       Date:  2022-09-26       Impact factor: 6.208

7.  Prediction of Liver Triglyceride Content in Early Lactation Multiparous Holstein Cows Using Blood Metabolite, Mineral, and Protein Biomarker Concentrations.

Authors:  Ryan S Pralle; Henry T Holdorf; Rafael Caputo Oliveira; Claira R Seely; Sophia J Kendall; Heather M White
Journal:  Animals (Basel)       Date:  2022-09-24       Impact factor: 3.231

Review 8.  'Magnesium'-the master cation-as a drug-possibilities and evidences.

Authors:  Aparna Ann Mathew; Rajitha Panonnummal
Journal:  Biometals       Date:  2021-07-02       Impact factor: 2.949

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.